Rapport Therapeutics Overview
Rapport Therapeutics Target Price
See Rapport Therapeutics's analyst price targets ($71) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$25.93
Average Target Price
$70.64
172.4% upside
172.4% upside11 analysts in the last 4 months
High: $89 | Low: $50
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-10-21 | Wells FargoBen Burnett | $50 | 92.8% upside |  |
| 2026-10-20 | GuggenheimDelma Caiati | $70 | 170% upside | |
| 2026-10-20 | Raymond James | $86 | 231.7% upside | |
| 2026-10-20 | BTIGKambiz Yazdi | $89 | 243.2% upside | |
| 2026-10-15 | UBS | $71 | 173.8% upside | |
| 2026-10-15 | Wolfe Research | $50 | 92.8% upside | |
| 2026-10-05 | Guggenheim | $65 | 150.7% upside | |
| 2026-09-23 | UBS | $80 | 208.5% upside | |
| 2026-09-16 | BTIGKambiz Yazdi | $75 | 189.2% upside | |
| 2026-08-17 | Raymond JamesTiago Fauth | $75 | 189.2% upside | |
| 2026-08-12 | H.C. WainwrightDouglas Tsao | $66 | 154.5% upside | |
| 2026-06-24 | Leerink Partners | $52 | 100.5% upside | |
| 2026-05-21 | BTIG | $65 | 150.7% upside | |
| 2026-05-18 | Truist Financial | $56 | 116% upside | |
| 2026-04-10 | Raymond JamesTiago Fauth | $66 | 154.5% upside | |
| 2026-03-09 | BTIGKambiz Yazdi | $47 | 81.3% upside | |
| 2026-02-02 | Wells FargoBenjamin Burnett | $43 | 65.8% upside | |
| 2025-12-19 | Wells Fargo | $51 | 96.7% upside | |
| 2025-12-09 | H.C. WainwrightDouglas Tsao | $40 | 54.3% upside | |
| 2025-09-16 | Truist FinancialJoon Lee | $44 | 69.7% upside | |
| 2024-07-02 | JefferiesAndrew Tsai | $35 | 35% upside | |
| 2024-07-02 | Stifel NicolausPaul Matteis | $35 | 35% upside | |